首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses
【2h】

Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses

机译:免疫调节药甲氨蝶呤用于治疗基孔肯雅热后的慢性炎性风湿病患者不会损害滑膜抗病毒和骨修复反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chikungunya virus (CHIKV) is a mosquito-transmitted RNA alphavirus causing major outbreaks of infectious chronic inflammatory rheumatisms (CIR). Recently, methotrexate (MTX), a disease modifying anti-rheumatic drug has been used successfully to treat patients suffering from rheumatoid-like arthritis post-CHIK but its immunomodulatory activity in the context of viral persistence has been a matter of concerns. We herein used a model of primary human synovial fibroblasts (HSF) and the synthetic molecule polyriboinosinic:polyribocytidylic acid (PIC) to mimic chronic infectious settings in the joints of CHIKV infected patients. The innate antiviral immune and inflammatory responses were investigated in response to MTX used at the therapeutic concentration of 1 μM. We found that MTX did not affect cellular viability as indicated by the LDH release assay. By quantitative RT-PCR, we observed that HSF responded robustly to PIC by increasing ISG15 and IFNβ mRNA levels. Furthermore, PIC upregulated the mRNA expression of two of the major pattern recognition receptors, RIG-I and MDA5 involved in the innate immune detection of viral RNA. MTX did not impact the antiviral response of PIC on ISG15, IFNβ, RIG-I and MDA5 mRNA expressions. MTX alone or combined with PIC did not affect the expression of proinflammatory CCL2 and CXCL8 chemokines. PIC strongly upregulated the mRNA and protein expression of osteoclastogenic factors (IL-6, GM-CSF but not RANKL). Critically, MTX treatment alone or combined with PIC did not affect the expression of all three tested osteoclastogenic cytokines. We found that MTX alone did not increase the capacity of CHIKV to infect and replicate in HSF. In conclusion, our study argues for a beneficial effect of MTX to treat CIR post-CHIKV given that it does not critically impact the antiviral, the proinflammatory and the bone tissue remodeling responses of synovial cells.
机译:基孔肯雅病毒(CHIKV)是一种蚊子传播的RNAα病毒,可引起传染性慢性炎性风湿病(CIR)的大规模爆发。最近,甲氨蝶呤(MTX)是一种抗疾病的抗风湿药,已成功用于治疗Chik后风湿性关节炎的患者,但在病毒持续存在的情况下其免疫调节活性已成为人们关注的问题。我们在本文中使用了原发性人类滑膜成纤维细胞(HSF)和合成分子聚核糖核酸:聚核糖酸(PIC)的模型来模拟CHIKV感染患者关节的慢性感染情况。对治疗浓度为1μM的MTX的先天性抗病毒免疫和炎症反应进行了研究。我们发现,如LDH释放试验所示,MTX不会影响细胞活力。通过定量RT-PCR,我们观察到HSF通过增加ISG15和IFNβmRNA水平对PIC产生强烈反应。此外,PIC上调了参与病毒RNA固有免疫检测的两种主要模式识别受体RIG-1和MDA5的mRNA表达。 MTX不会影响PIC对ISG15,IFNβ,RIG-I和MDA5 mRNA表达的抗病毒反应。单独或与PIC联合使用MTX不会影响促炎性CCL2和CXCL8趋化因子的表达。 PIC强烈上调破骨细胞因子(IL-6,GM-CSF,但不包括RANKL)的mRNA和蛋白表达。至关重要的是,单独或与PIC联合使用MTX治疗不会影响所有三种测试的破骨细胞生成细胞因子的表达。我们发现仅MTX不会增加CHIKV在HSF中感染和复制的能力。总而言之,我们的研究认为MTX可以治疗CHIKV后CIR的有益作用,因为它不会严重影响滑膜细胞的抗病毒,促炎和骨组织重塑反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号